Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Rhythm Biosciences Ltd. ( (AU:RHY) ).
Rhythm Biosciences Ltd has entered into a marketing partnership with Catch Bio, a cancer prevention platform, to introduce its geneTypeTM Cancer Risk Assessment Test to Catch Bio’s US member base. This collaboration enhances Catch Bio’s platform by integrating Rhythm’s clinically validated polygenic risk assessment for multiple cancers, supporting Rhythm’s US market expansion strategy. The partnership signifies a commercial milestone for Rhythm, reflecting growing market acceptance of geneTypeTM and expanding its presence in a key global market. The integration of geneTypeTM with Catch Bio’s AI-driven risk model offers a comprehensive risk profile for proactive cancer prevention, marking a significant step in Rhythm’s commitment to early cancer detection.
The most recent analyst rating on (AU:RHY) stock is a Hold with a A$0.09 price target. To see the full list of analyst forecasts on Rhythm Biosciences Ltd. stock, see the AU:RHY Stock Forecast page.
More about Rhythm Biosciences Ltd.
Rhythm Biosciences Ltd is an Australian medical diagnostics company focused on developing simple, affordable blood tests for early cancer detection. Founded in 2017 and headquartered in Melbourne, the company aims to improve patient outcomes by detecting cancers at the earliest possible stage, thereby reducing the global cancer burden and saving lives. Rhythm Biosciences collaborates with global partners to commercialize and distribute its diagnostic solutions.
Average Trading Volume: 336,941
Technical Sentiment Signal: Sell
Current Market Cap: A$26.62M
For an in-depth examination of RHY stock, go to TipRanks’ Overview page.